RapaLink-1, a bivalent third generation mTOR inhibitor, which combines rapamycin with INK128 (Sapanisertib) by an inert chemical linker, has also shown great efficacy in MYCN-driven brain tumor models (150). This evidence concerns the gene MTOR and brain neoplasm.